Brookdale Senior Living Inc. (BKD) Q1 2026 Earnings Call Transcript
Here is how Brookdale Senior Living (BKD) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
BKD's Q1'26 occupancy climbs to 82.1%, marking a fourth straight quarter of year-over-year gains despite a slight dip from Q4'25.
Brookdale (BKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Brookdale Senior Living Inc. (BKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BKD, LUMN and GOLD screen as momentum anomaly picks after market turmoil, pairing strong one-year gains with sharp weekly pullbacks.
The mean of analysts' price targets for Brookdale (BKD) points to a 27.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Brookdale Senior Living Inc. (BKD) Q4 2025 Earnings Call Transcript
Brookdale (BKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VRT, NTRS and BKD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 19th, 2026.
BKD, DVA, VRT, WASH and GBOOY have been added to the Zacks Rank #1 (Strong Buy) List on February 19th, 2026.
Brookdale Senior Living is transitioning from stabilization to operational leverage, with incremental revenue now flowing directly to the bottom line. BKD's turnaround is validated by 20.4% adjusted EBITDA growth, improving free cash flow, and rising occupancy, despite headline net losses from non-cash charges. Recent debt refinancing eliminates near-term liquidity risk, locks in fixed rates, and signals institutional confidence in BKD's asset quality.